Acorah Software Products - Accounts Production 16.7.461 false true false true No description of principal activity 12 April 2024 30 April 2025 30 April 2025 15638821 Dr Rhys Welnitschuk iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 15638821 2024-04-11 15638821 2025-04-30 15638821 2024-04-12 2025-04-30 15638821 frs-core:CurrentFinancialInstruments 2025-04-30 15638821 frs-bus:PrivateLimitedCompanyLtd 2024-04-12 2025-04-30 15638821 frs-bus:FilletedAccounts 2024-04-12 2025-04-30 15638821 frs-bus:Micro-entities 2024-04-12 2025-04-30 15638821 frs-bus:AuditExempt-NoAccountantsReport 2024-04-12 2025-04-30 15638821 frs-bus:Director1 2024-04-12 2025-04-30
Registered number: 15638821
Rhesus Medicine Ltd
Unaudited Financial Statements
For the Period 12 April 2024 to 30 April 2025
Tax Driven Accountants
Rhesus Medicine Ltd
Balance Sheet
As At 30 April 2025
Balance Sheet
Registered number: 15638821

| 30 April 2025
--- | ---
|  | £
Current assets |  | 40,279
Creditors: Amounts Falling Due Within One Year |  | (17,667 )
NET CURRENT ASSETS |  | 22,612
TOTAL ASSETS LESS CURRENT LIABILITIES |  | 22,612
NET ASSETS |  | 22,612
CAPITAL AND RESERVES |  | 22,612

## Notes

1. General Information
Rhesus Medicine Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 15638821 . The registered office is 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ.
2. Average Number of Employees
Average number of employees, including directors, during the period was: 1
1
For the period ending 30 April 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
On behalf of the board

Dr Rhys Welnitschuk Director
18/06/2025